STOCK TITAN

Madrigal (MDGL) 10b5-1 insider sales show multimillion proceeds in July–Aug 2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July–August 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.

Positive

  • Form 144 filed providing public disclosure of the proposed sale of 43,263 shares
  • Broker identified as Morgan Stanley Smith Barney LLC, giving execution routing details
  • Securities were acquired by exercise of stock options and payment was in cash on the stated date

Negative

  • Multiple sizeable 10b5-1 insider sales in the past three months, including Rebecca Taub: 26,444 shares for $9,347,062.51 on 07/16/2025
  • Multiple sizeable 10b5-1 insider sales in the past three months, including Paul A. Friedman: 26,176 shares for $9,252,542.95 on 07/16/2025
  • Several filer/issuer identifying fields in the provided form appear blank, limiting immediate verification from this document alone

Insights

TL;DR: Multiple scheduled insider sales disclosed; Form 144 shows a proposed sale of 43,263 shares valued at $15.12M.

The filing documents a straightforward Form 144 notice for the proposed public sale of 43,263 common shares via Morgan Stanley Smith Barney with a stated market value of $15,120,418.50. The shares were acquired and are to be sold on 08/12/2025 via exercise of stock options and paid in cash. The form also enumerates several 10b5-1 plan sales by named insiders in July–August 2025, producing multi-million dollar gross proceeds. This is disclosure of insider liquidity rather than an operational update.

TL;DR: Disclosure includes multiple insider 10b5-1 sales and required certifications, though some filer/issuer fields are blank.

The notice includes the statutory signature and representation language and identifies the broker and transaction details. It documents acquisition by option exercise and lists recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman with exact dates and proceeds. The form as provided omits certain filer/issuer identification entries, which should be complete for full transparency in public filings.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Madrigal (MDGL) report on this Form 144?

The filing reports a proposed sale of 43,263 common shares with an aggregate market value of $15,120,418.50, and states 22,289,014 shares outstanding. The approximate sale date is 08/12/2025.

Who is the broker handling the proposed sale?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor, New York NY 10004.

How were the securities acquired?

The securities were acquired on 08/12/2025 by exercise of stock options, and the filing states payment was made in cash on that date.

Have insiders sold shares recently under 10b5-1 plans?

Yes. The filing lists multiple 10b5-1 sales by Rebecca Taub and Paul A. Friedman in July–August 2025, including large transactions on 07/16/2025 and sales on 07/17, 07/18, and 08/11/2025 with multi-million dollar gross proceeds.

Are there any missing details in the provided filing?

Yes. Certain filer and issuer identification fields in the provided form (for example, Filer CIK and filer name) appear blank in the document content supplied.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Latest SEC Filings

MDGL Stock Data

13.60B
20.97M
7.7%
107.92%
18.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN